NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.2280 +0.23 (+3.29 %)
(As of 06/18/2018 11:20 AM ET)
Previous Close$7.00
Today's Range$7.00 - $7.2280
52-Week Range$6.15 - $11.34
Volume6,116 shs
Average Volume26,297 shs
Market Capitalization$101.10 million
P/E Ratio-9.15
Dividend YieldN/A

About Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals logoOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio4.48
Quick Ratio4.48


Trailing P/E Ratio-9.15
Forward P/E Ratio-7.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.46 million
Price / Sales42.43
Cash FlowN/A
Price / CashN/A
Book Value$1.44 per share
Price / Book5.02


EPS (Most Recent Fiscal Year)($0.79)
Net Income$-10,480,000.00
Net Margins-165.00%
Return on Equity-49.15%
Return on Assets-25.54%


Outstanding Shares14,440,000

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Sunday, April, 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.11. The biotechnology company earned $0.60 million during the quarter, compared to analysts' expectations of $0.62 million. Oramed Pharmaceuticals had a negative return on equity of 49.15% and a negative net margin of 165.00%. View Oramed Pharmaceuticals' Earnings History.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, July, 5th 2018. View Earnings Estimates for Oramed Pharmaceuticals.

What price target have analysts set for ORMP?

2 brokerages have issued 1 year target prices for Oramed Pharmaceuticals' shares. Their forecasts range from $20.00 to $25.00. On average, they expect Oramed Pharmaceuticals' share price to reach $22.50 in the next twelve months. View Analyst Ratings for Oramed Pharmaceuticals.

Who are some of Oramed Pharmaceuticals' key competitors?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the folowing people:
  • Mr. Nadav Kidron Esq., Pres, CEO & Exec. Director (Age 44)
  • Mr. Joshua Hexter, COO & VP of Bus. Devel. (Age 48)
  • Dr. Miriam Kidron Ph.D., Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 78)
  • Ms. Hilla Eisenberg CPA, CFO, Treasurer, Sec. and Principal Financial & Accounting Officer (Age 34)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

Has Oramed Pharmaceuticals been receiving favorable news coverage?

Media coverage about ORMP stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oramed Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 41.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $7.2280.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $101.10 million and generates $2.46 million in revenue each year. The biotechnology company earns $-10,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Oramed Pharmaceuticals employs 14 workers across the globe.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is HI-TECH PARK 2/4 GIVAT-RAM PO BOX 39098, JERUSALEM L3, 91390. The biotechnology company can be reached via phone at 011-972-2-566-0001 or via email at [email protected]

MarketBeat Community Rating for Oramed Pharmaceuticals (ORMP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.